Venetoclax combined with dose-reduced HAD as induction treatment for patients with de-novo acute myeloid leukemia.

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML2025 · 3 citations
2. 2Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience2026
3. 3Reduced intensive chemotherapy combined with venetoclax in adult patients with Acute Myeloid Leukemia: A retrospective single-center analysis2025
4. 4Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial2025 · 1 citations
5. 5Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025